Efficacy of 577 nm subthreshold micropulse laser in central serous chorioretinopathy

Abstract To evaluate the effects of 577 nm subthreshold micropulse laser (SML) on central serous chorioretinopathy (CSC) and to investigate the possible factors associated with the efficacy of SML in CSC. CSC patients who received SML between July 2021 and March 2022 were included. The rate of complete resolution of subretinal fluid (SRF) at week 6 and week 12 after SML were assessed. The association between baseline factors and the outcome of SML was also investigated. The difference in best corrected visual acuity (BCVA) and the sub foveal choroidal thickness (SFCT) between 12 weeks after SML and those at baseline were assessed. Thirty-five patients(35 eyes)were included. The rate of complete resolution of SRF after SML in CSC patients was 25.7% at week 6 and 40.0% at week 12. Among baseline factors, only longer symptom duration was independently associated with persistent SRF after SML (aOR = 1.431, P = 0.023). The BCVA improved and SFCT decreased significantly at 12 weeks after SML (t = 3.274, P = 0.002, and t = 3.110, P = 0.004, respectively). The 577 nm SML was an effective method to promote resolution of SRF in CSC eyes, especially those with short symptom duration.